InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.

Therapies targeting IL-23 have demonstrated good efficacy for moderate/severe plaque psoriasis and have become a treatment staple ... to patients who achieved the best results showed that 33% ...

for the treatment of moderate-to-severe plaque psoriasis in China. This is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study, designed to evaluate the efficacy ...

Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis ... and commercializing first-in-class and/or best-in-class drugs for the ...

For example, in studies of people using Cosentyx for plaque psoriasis ... treatment, talk with your doctor. They can help you understand what to expect and can recommend the best approach for ...

"More than six million people in the U.S. live with plaque psoriasis. So I'm definitely not alone in this journey, and I just ...

Late-breaking Oral Presentation Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis ... best-in-class drugs for the ...

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.